Recruiting
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants - IM039-1001
Actualizada: 2 mayo, 2023 | ClinicalTrials.gov
Imprimir Resumen
Detalles del estudio
Fase
Géneros
Rango de edad
Ubicación (es)
Recruiting
Opciones de tratamiento
Inclusion Criteria: - Participants must be ethnically Japanese (both biological parents are ethnically Japanese). - Healthy male and female participants as determined by no clinically significant deviation from normal in medical history, physical examination, 12-lead ECGs, or clinical laboratory determinations. - Body mass index (BMI) between 18 and 30 kg/m2, inclusive, at screening. Exclusion Criteria: - Any significant acute or chronic medical illness. - Any major surgery within 4 weeks prior to study drug administration, or any surgery planned during the course of the study. - Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status (eg, history of splenectomy). Other protocol-defined inclusion/exclusion criteria apply.
Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica
